ストックスクリーナーアプリを入手
24.58
2.03%
-0.51
プレマーケット:
24.99
0.41
+1.67%
Arcutis Biotherapeutics Inc (ARQT) 最新ニュース
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 - The Manila Times
Arcutis to give business update with Q1 results after market close May 6 - Stock Titan
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Arcutis Biotherapeutics (ARQT) price target increased by 10.24% to 35.70 - MSN
Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive - Yahoo Finance
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate - ChartMill
(ARQT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN
Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge? - Yahoo Finance
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know - The Globe and Mail
Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should Know - The Motley Fool
How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 Targets - Yahoo Finance
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales - Bitget
Aberdeen Group plc Sells 88,637 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Perpetual Ltd Sells 1,113,976 Shares of Arcutis Biotherapeutics, Inc. $ARQT - marketbeat.com
Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics Inc (ARQT) - GuruFocus
Insider Selling: Arcutis Biotherapeutics (NASDAQ:ARQT) Director Sells 10,000 Shares of Stock - marketbeat.com
Planned sale: Arcutis (ARQT) director disposes of 10,000 shares - Stock Titan
Responsive Playbooks and the ARQT Inflection - Stock Traders Daily
Arcutis Biotherapeutics, Inc.Common stock (NQ: ARQT - The Chronicle-Journal
Insider sales reported at Arcutis Biotherapeutics (NASDAQ: ARQT) — two 10,000-share disposals - Stock Titan
Analysts Are Optimistic We'll See A Profit From Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) - Moomoo
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference - The Manila Times
Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 8.7%Here's Why - MarketBeat
Zevenbergen Capital Investments LLC Acquires Shares of 418,035 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis executives join Needham virtual health conference April 14 - Stock Titan
Tudor Investment Corp ET AL Invests $1.32 Million in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Aug Big Picture: What are the future prospects of Arcutis Biotherapeutics Inc2026 Institutional & High Accuracy Trade Signal Alerts - baoquankhu1.vn
Arcutis presents trial data on roflumilast cream for infants By Investing.com - Investing.com Canada
Arcutis presents trial data on roflumilast cream for infants - Investing.com
Arcutis Biotherapeutics Reports Positive Phase 2 Trial Results for ZORYVE® Cream in Infants with Atopic Dermatitis - Quiver Quantitative
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting - The Manila Times
Nearly half of infants saw eczema itch ease in 10 minutes - Stock Titan
Nordea Investment Management AB Acquires New Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
[SCHEDULE 13G/A] Arcutis Biotherapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Silverleafe Capital Partners LLC Increases Stock Holdings in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Understanding the Setup: (ARQT) and Scalable Risk - Stock Traders Daily
Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data - Yahoo Finance
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Weakness - simplywall.st
Arcutis (ARQT) Announces Long-Term Phase 3 Data for ZORYVE Cream in Children - Insider Monkey
Arcutis to Present New Clinical Data in a Late-Breaking Podium Presentation and Scientific Posters at the 2026 American Academy of Dermatology Annual Meeting - Bitget
Arcutis Biotherapeutics (ARQT) Unveils New Trial Data at Dermato - GuruFocus
New eczema treatment data in infants and kids set for 2026 AAD - Stock Titan
2.69%
0.25%
大文字化:
|
ボリューム (24 時間):